“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of
Producing high quality affordable
and accessible biologics
Lupin Appoints Jon Stelzmiller as President of US SpecialtyBusiness
Mumbai, Somerset NJ, September 25, 2019: Pharma major Lupin Limited (Lupin) announced the appointment of Jon Stelzmiller as the President of its U.S. Specialty business.
Jon brings to Lupin over 30 years of experience in the specialty segment and will be replacing Nicholas Hart. Jon has a proven track record of building highperforming teams and launching 18 major brandsacross 14 different therapeutic areas including Women’s Health, Oncology andAnti-Infectives. Most recently, Jon was SVP &General Manager — Women’s Healthcare atBayer where he helped build and lead abillion-dollar women’s health business in the U.S. Prior toBayer, Jon spent 12 years at Pfizer Inc. in roles of increasing commercial responsibilities in Specialty areas including Institutional sales and market access. Jon spent his early career at The UpjohnCompany and Pharmacia Corporation in various sales and sales leadership positions. Jon holds a Bachelor of Science inBacteriology from North Dakota State University.
Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin said, “Jon’s extensive experience in the pharmaceutical industry,particularly in women’s health segment in the U.S.,will be a great asset for Lupinas we build our specialty business, includingSOLOSEC®.We are delighted to welcome Jononboard.”
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).
For the financial year ended 31st March, 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries, please contact –
VP – Corporate Communications
Ph: +91-22-66402531 / 8291013225
Head – Investor Relations
*Safe Harbor Statement